LAUSANNE, Switzerland–(BUSINESS WIRE)–ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that it has terminated the Phase I clinical trial to evaluate its antibody drug conjugate (ADC) ADCT-502 in patients with advanced solid …
Tag Archives: ADC Therapeutics
April, 2018
March, 2015
-
16 March
ADC Therapeutics Submits IND for its Novel Antibody Drug Conjugate
Today, Cancer drugmaker ADC Therapeutics Sarl announced that it has filed its first application to US health regulators for its lymphoma drug. The company said that it has filed an Investigational New Drug Application (IND) to the US Food and Drug Administration (FDA) for a Phase I clinical trial for …